Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS

"Compared with placebo, treatment with alogliptin resulted in similar rates of the primary endpoint, which was a composite of cardiovascular death, myocardial infarction, and stroke ," said the chair of the study's steering committee William B. White, MD, from the University of Connecticut School of Medicine in Farmington, Connecticut, USA."

http://www.sciencedaily.com/releases/2013/09/130902102011.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fdiabetes+%28ScienceDaily%3A+Health+%26+Medicine+News+--+Diabetes%29